

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/955,414	09/18/2001	Nancy L. Parenteau	68603-121	1042	
23483 7	590 09/21/2004		EXAMINER		
WILMER CUTLER PICKERING HALE AND DORR LLP			PREBILIC, PAUL B		
60 STATE STREET BOSTON, MA 02109			ART UNIT	PAPER NUMBER	
,			3738		
			DATE MAILED: 09/21/2004	DATE MAILED: 09/21/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

			M				
		Application No.	Applicant(s)				
		09/955,414	PARENTEAU ET AL.				
Office Action Summary		Examiner	Art Unit	_			
		Paul B. Prebilic	3738				
	The MAILING DATE of this communication a	appears on the cover sheet wi	th the correspondence address	_			
Period for	• •						
THE - Exte after - If the - If NO - Faile Any	IORTENED STATUTORY PERIOD FOR REF MAILING DATE OF THIS COMMUNICATION insions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a lead of the property will, by state of the property will, by state of the property of th	N. 1.136(a). In no event, however, may a re reply within the statutory minimum of thirt od will apply and will expire SIX (6) MON tute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).				
Status			•				
1)⊠	Responsive to communication(s) filed on 09	) August 2004.					
2a) ☐	This action is <b>FINAL</b> 2b)⊠ T	his action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice unde	er <i>Ex parte</i> Quayle, 1935 C.D	. 11, 453 O.G. 213.				
Disposit	ion of Claims						
4)⊠	Claim(s) 1,3 and 7 is/are pending in the app	olication.					
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) 🗌	Claim(s) is/are allowed.						
6)⊠	Claim(s) 1.3 and 7 is/are rejected.						
7)	Claim(s) is/are objected to.						
8) 🗌	Claim(s) are subject to restriction and	d/or election requirement.	N.				
Applicat	tion Papers						
9)[	The specification is objected to by the Exam	iner.					
10)	The drawing(s) filed on is/are: a) a	accepted or b) objected to	by the Examiner.				
	Applicant may not request that any objection to t	he drawing(s) be held in abeyar	nce. See 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including the corn	rection is required if the drawing	(s) is objected to. See 37 CFR 1.121(d).				
11)	The oath or declaration is objected to by the	Examiner. Note the attached	d Office Action or form PTO-152.				
Priority	under 35 U.S.C. § 119						
12)	Acknowledgment is made of a claim for fore	ign priority under 35 U.S.C. §	§ 119(a)-(d) or (f).				
<b>a</b> )	) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority docume	ents have been received.					
	2. Certified copies of the priority docume	ents have been received in A	pplication No				
	3. Copies of the certified copies of the p	riority documents have been	received in this National Stage				
	application from the International Bur	eau (PCT Rule 17.2(a)).					
*	See the attached detailed Office action for a	list of the certified copies not	received.	,			
Attachme	• •	_					
	ce of References Cited (PTO-892)		Summary (PTO-413) s)/Mail Date				
3) 🔲 Info	ce of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449 or PTO/SB/ er No(s)/Mail Date		nformal Patent Application (PTO-152)				

Application/Control Number: 09/955,414

Art Unit: 3738

A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on August 9, 2004 has been entered.

The indicated allowability of previous claim 5 is withdrawn in view of a new interpretation of previous claim 5; claim 1 was rewritten to incorporate the limitations of claim 5. In particular, the language of lines 10-14 of amended claim 1 beginning at "which is synthesized . . . " is being treated as a product-by-process. For this reason, the claims only clearly require a layer of extracellular matrix for the construct as claimed; see MPEP 2113 which is incorporated herein be reference. Since the Applicants have not met their burden to show that the process claimed results in an unobvious product from that of Doillon (and now Ferree), it is the Examiner's position that the claims are obvious in view of the rejection set forth below.

# Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 3, and 7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Regarding claims 1, 3, and 7, on lines 11-12 of

Application/Control Number: 09/955,414

Art Unit: 3738

claim 1, the newly added language "with the cultured fibroblast cells contained with the synthesized extracellular matrix layer" is indefinite because it is unclear whether the cells are present merely during the process of making (lines 10-14 beginning at "which . ") or are positively required in the construct that is grafted to close the opening as claimed. The Examiner will the claim as merely requiring the fibroblast during the process of making the construct and not necessarily in the construct used in the claimed method.

### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 3, and 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Stoval (WO/04720) in view of Doillon et al (US 5,863,984) or Ferree (US 6,352,557). Stoval discloses a method of forming an opening in an annulus fibrosis (see page 10, line 1 to page 11, line12 and Figure 2), removing at least a portion of the nucleus pulposus (see supra), and grafting a cultured connective tissue construct to close the opening (see supra as well as page 2, lines 10-18, page 3, lines 7-14, and page 4, lines 10-15). However, Stoval fails to clearly disclose a bioremoldable construct as claimed. However, Doillon teaches that it was known to make cultured connective tissue constructs with fibroblasts in the repair of connective tissue; see the abstract, Figures 4A-4E, column 15, lines 41-51, column 16, lines 8-62, and column 19, lines 35-

Application/Control Number: 09/955,414

24 and see the abstract of Ferree.

Art Unit: 3738

44. Likewise, Ferree teaches that is was known to graft constructs of extracellular matrix and cells into spinal disks; see the abstract and column 1, lines 59-67. Therefore, it is the Examiner's position that it would have been prima fascia obvious to use the cultured connective tissue construct of Doillon or the constructs of Ferree as the opening cover for the same reasons that Doillon uses the same; see column 3, lines 21-

With regard to claim 3, extracellular matrix contains collagen, and thus, the claim language is fully met.

### Response to Arguments

Applicant's arguments with respect to claims 1, 3, and 7 have been considered but are most in view of the new ground(s) of rejection based upon a new interpretation.

#### Conclusion

Applicant should specifically point out the support for any amendments made to the disclosure, including the claims (MPEP 714.02 and 2163.06). Due to the procedure outlined in MPEP 2163.06 for interpreting claims, it is noted that other art may be applicable under 35 USC 102 of 35 USC 103(a) once the aforementioned issue(s) is/are addressed.

Applicant is respectfully requested to provide a list of all copending applications that set forth similar subject matter to the present claims. A copy of such copending claims is respectfully requested in response to this Office action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Paul B. Prebilic whose telephone number is (703) 308-2905. The examiner can normally be reached on 6:30-5:00 M-Th.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, McDermott Corrine can be reached on (703) 308-2111. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 3738

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Paul Prebilic
Primary Examiner
Art Unit 3738